Clinical Research Directory
Browse clinical research sites, groups, and studies.
Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy
Sponsor: University Hospital, Clermont-Ferrand
Summary
French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.
Official title: Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
321
Start Date
2023-11-17
Completion Date
2028-11-17
Last Updated
2024-09-27
Healthy Volunteers
No
Conditions
Interventions
Blood and bone marrow sample
Individual biological aging determined by DNA methylation analysis will be assessed at D0, M3 and M12. An optional bone marrow sample will be taken during the myelogram performed at diagnosis. Individual fragility and quality of life will be assessed using geriatric tools at D0, M6, M12, M24 and M36
Locations (17)
CHU Annecy-Genevois
Annecy, France
Institut Bergonié
Bordeaux, France
CHU Caen
Caen, France
CHU de Clermont-Ferrand
Clermont-Ferrand, France
CHU Créteil
Créteil, France
CHU Grenoble Alpes
Grenoble, France
Centre Hospitalier Emile Roux
Le Puy-en-Velay, France
CHRU Lille
Lille, France
CHU Limoges
Limoges, France
Centre Léon Bérard
Lyon, France
Institut Paoli-Calmettes
Marseille, France
CHU Nancy
Nancy, France
Groupe Hospitalier Paris Saclay - Site de Bicêtre
Paris, France
CHU Rennes
Rennes, France
CHU Saint-Etienne
Saint-Etienne, France
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France
CHU Versailles
Versailles, France